What makes TMB an ambivalent biomarker for immunotherapy? A subtle mismatch between the sample-based design of variant callers and real clinical cohort

Tumor mutation burden (TMB) is a widely recognized biomarker for predicting the efficacy of immunotherapy. However, its use still remains highly controversial. In this study, we examine the underlying causes of this controversy based on clinical needs. By tracing the source of the TMB errors and ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yuqian, Wang, Shenjie, Wang, Yixuan, Li, Yifei, Zhu, Xiaoyan, Lai, Xin, Zhang, Xuanping, Li, Xuqi, Xiao, Xiao, Wang, Jiayin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248171/
https://www.ncbi.nlm.nih.gov/pubmed/37304296
http://dx.doi.org/10.3389/fimmu.2023.1151224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10248171/
https://www.ncbi.nlm.nih.gov/pubmed/37304296
http://dx.doi.org/10.3389/fimmu.2023.1151224

Ejemplares similares